Inluriyo FDA Approval History
FDA Approved: Yes (First approved September 25, 2025)
Brand name: Inluriyo
Generic name: imlunestrant
Dosage form: Tablets
Company: Eli Lilly and Company
Inluriyo (imlunestrant) is an estrogen receptor antagonist indicated for the treatment of adults with ER-positive, HER2-negative, ESR1- mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Development timeline for Inluriyo
| Date | Article |
|---|---|
| Sep 25, 2025 | Approval FDA Approves Inluriyo (imlunestrant) for Adults with ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.